Scarica l'app Stockscreener
46.24
2.19%
0.99
Dopo l'orario di chiusura:
46.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
PTC upgraded to outperform by RBC on Novartis deal - MSN
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down - MSN
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN
PTC Therapeutics Submits Vantiquinone NDA To FDA - Contract Pharma
PTC Therapeutics submits FDA application for FA treatment - Investing.com
PTC Therapeutics Seeks FDA Approval for Groundbreaking Friedreich Ataxia Treatment in Children - StockTitan
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
PTC Therapeutics Submits Vantiquinone NDA to FDA - Contract Pharma
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to "Hold" at StockNews.com - MarketBeat
PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia - Marketscreener.com
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
PTC Therapeutics Grants New Employee Stock Options and RSUs in Strategic Talent Acquisition Move - StockTitan
PTC Therapeutics' SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Y Intercept Hong Kong Ltd Sells 18,312 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
State Street Corp Purchases 149,700 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Morgan Stanley Upgrades PTC Therapeutics (PTCT) - MSN
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
PTC Therapeutics upgraded to Overweight at Morgan Stanley - MSN
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Overweight at Morgan Stanley - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast - BioCentury
Two Sigma Advisers LP Grows Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Fmr LLC Trims Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Wellington Management Group LLP Sells 315,807 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
BNP Paribas Financial Markets Sells 54,655 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
At $1B, PTC-Novartis deal ties record for cash up front - BioCentury
Janus Henderson Group PLC Sells 1,111,342 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Global Leigh Syndrome Treatment Market Outlook: Key Trends, - openPR
PTC Therapeutics (STU:BH3) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
PTC Therapeutics (STU:BH3) 9-Day RSI : 64.15 (As of Dec. 05, 2024) - GuruFocus.com
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy - MSN
Ptc Therapeutics exec VP sells shares worth $5 million By Investing.com - Investing.com Canada
PTC Therapeutics director Jerome Zeldis sells $1.24m in stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics price target raised to $41 from $31 at BofA - MSN
Ptc Therapeutics' chief accounting officer sells shares worth $921,585 By Investing.com - Investing.com Canada
Insider Sell Alert: Christine Utter Sells 17,800 Shares of PTC T - GuruFocus.com
Insider Sell Alert: Jerome Zeldis Sells 24,000 Shares of PTC The - GuruFocus.com
Ptc Therapeutics exec VP sells shares worth $5 million - Investing.com
Ptc Therapeutics' chief accounting officer sells shares worth $921,585 - Investing.com
PTC Therapeutics director Jerome Zeldis sells $1.24m in stock - Investing.com
PTC Therapeutics' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com Nigeria
PTC Therapeutics price target raised to $70 from $52 at Baird - MSN
Parkman Healthcare Partners LLC Takes $7.23 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics price target raised to $71 from $47 at UBS - Yahoo Finance
Jacobs Levy Equity Management Inc. Sells 229,494 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Ptc Therapeutics' chief technical officer sells shares worth $3.6 million - Investing.com
PTC Therapeutics' SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone - MSN
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug - MSN
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):